ES2167561T3 - Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos. - Google Patents

Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.

Info

Publication number
ES2167561T3
ES2167561T3 ES96913954T ES96913954T ES2167561T3 ES 2167561 T3 ES2167561 T3 ES 2167561T3 ES 96913954 T ES96913954 T ES 96913954T ES 96913954 T ES96913954 T ES 96913954T ES 2167561 T3 ES2167561 T3 ES 2167561T3
Authority
ES
Spain
Prior art keywords
nucleic acid
acid molecules
molecula
complexed
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913954T
Other languages
English (en)
Inventor
Yannick Guilloux
Francine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Institut National de la Sante et de la Recherche Medicale INSERM
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Institut National de la Sante et de la Recherche Medicale INSERM
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Institut National de la Sante et de la Recherche Medicale INSERM, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2167561T3 publication Critical patent/ES2167561T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCUBREN NUEVOS PRECURSORES DE ANTIGENO DE RECHAZO TUMORAL, Y LAS MOLECULAS DE ACIDO NUCLEICO QUE LOS CODIFICAN. ESTOS PRECURSORES DE ANTIGENO DE RECHAZO TUMORAL SE DEFINEN COMO PRECURSORES DE ANTIGENO DE RECHAZO DE TUMORES NAG, Y LAS MOLECULAS DE ACIDO NUCLEICO QUE LOS CODIFICAN SE DEFINEN COMO MOLECULAS CODIFICADORAS DE NAG. SE DESCRIBEN DIVERSOS USOS DIAGNOSTICOS Y TERAPEUTICOS DE LAS SECUENCIAS CODIFICANTES Y DE LAS MOLECULAS PRECURSORAS DE ANTIGENOS DE RECHAZO TUMORAL.
ES96913954T 1995-06-07 1996-05-07 Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos. Expired - Lifetime ES2167561T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof

Publications (1)

Publication Number Publication Date
ES2167561T3 true ES2167561T3 (es) 2002-05-16

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913954T Expired - Lifetime ES2167561T3 (es) 1995-06-07 1996-05-07 Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.

Country Status (12)

Country Link
US (3) US5821122A (es)
EP (1) EP0845032B1 (es)
JP (1) JP3849102B2 (es)
AT (1) ATE209680T1 (es)
AU (1) AU704934B2 (es)
CA (1) CA2223694C (es)
DE (1) DE69617440T2 (es)
DK (1) DK0845032T3 (es)
ES (1) ES2167561T3 (es)
PT (1) PT845032E (es)
WO (1) WO1996040039A2 (es)
ZA (1) ZA963907B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU2001229681A1 (en) * 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6607151B2 (en) * 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
PL1684801T3 (pl) * 2003-11-21 2010-07-30 Pasteur Institut Rekombinowana toksyna cyklazy adenylanowej indukuje odpowiedzi komórek T przeciwko antygenom nowotworowym
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
KR101076578B1 (ko) 2004-06-23 2011-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 2입자 착물을 이용한 생물학적 분자의 검출을 위한 방법 및조성물
WO2010080909A1 (en) 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
AU2013273987B2 (en) 2012-06-15 2018-08-09 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2014145992A1 (en) 2013-03-15 2014-09-18 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US10874621B2 (en) 2013-10-17 2020-12-29 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and therapeutic agents
EP3139909B1 (en) 2014-05-09 2025-01-01 Yale University Hyperbranched polyglycerol-coated particles
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3512563A1 (en) 2016-09-16 2019-07-24 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US12569497B2 (en) 2017-04-27 2026-03-10 The University Of Hong Kong Use of HCN inhibitors for treatment of cancer
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
WO2021092172A1 (en) 2019-11-05 2021-05-14 University Of Georgia Research Foundation, Inc. Functionally modified maytansinoids and compositions and methods of use thereof
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
CA3240407A1 (en) 2021-12-08 2023-06-07 Akiko Iwasaki Nanoparticle immunogenic compositions and vaccination methods
EP4469057A1 (en) 2022-01-28 2024-12-04 University of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
CN120129696A (zh) 2022-09-01 2025-06-10 乔治亚大学研究基金公司 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
EP4622631A1 (en) 2022-11-23 2025-10-01 University of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2151544T3 (es) * 1992-12-22 2001-01-01 Ludwig Inst Cancer Res Metodos para la deteccion y el tratamiento de individuos con celulas anormales que expresan antigenos peptidos hla-a2/tirosinasa.
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
CA2223694C (en) 2003-06-24
DE69617440D1 (de) 2002-01-10
ATE209680T1 (de) 2001-12-15
DE69617440T2 (de) 2002-08-08
EP0845032B1 (en) 2001-11-28
JP3849102B2 (ja) 2006-11-22
WO1996040039A3 (en) 2000-03-23
ZA963907B (en) 1997-03-11
PT845032E (pt) 2002-05-31
AU5676996A (en) 1996-12-30
EP0845032A4 (en) 2000-05-10
AU704934B2 (en) 1999-05-06
CA2223694A1 (en) 1996-12-19
JP2001520506A (ja) 2001-10-30
EP0845032A2 (en) 1998-06-03
WO1996040039A2 (en) 1996-12-19
US5886145A (en) 1999-03-23
US5821122A (en) 1998-10-13
DK0845032T3 (da) 2002-05-06
US5958711A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
DK0845032T3 (da) Isolerede nucleinsyremolekyler, peptider, der danner komplekser med MHC-molekyler HLA-A2, samt anvendelser
FI956019A0 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
DE69531866D1 (de) Isoliertes nukleinsäuremolekül, das für den tumorabstossungs-antigenvorläufer dage kodiert und seine verwendung
PT100515A (pt) Moleculas de acido nucleico, precursores de antigenios de rejeicao de tumores, antigenios da rejeicao de tumores e suas utilizacoes
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ES2174931T3 (es) Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1.
NO960158L (no) Fremgangsmåte til diagnostisering av en lidelse ved å bestemme ekspresjon av GAGE-tumor-rejeksjonsantigenforlöpere
ES2069527T3 (es) Anticuerpo quimerico especifico para el antigeno tumoral humano.
HUP9903951A2 (hu) Az anti-Fcalfa receptor ellenanyagokat tartalmazó terápiás multispecifikus vegyületek
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
DE69839443D1 (de) Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
ES2192602T3 (es) Molecula de acido nucleico aislada y truncada, que codifica el antigeno de rechazo tumurall gage.
ES2058908T3 (es) Procedimiento para la separacion y purificacion de sialil-transferasas.
DE68908223D1 (de) Verfahren zur herstellung von sehr reiner, dichter grossteiliger kieselsaeure.
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE265533T1 (de) Saeugetierchemokine
DE3855080D1 (de) Synoviale phospholipasen
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
PT979235E (pt) Molecula de acido nucleico isolada que codifica os antigenios percusores de rejeicao ao tumor mage-c1 e mage-c2 e utilizacoes destes
PT88913A (pt) Processo para a preparacao da proteina pp4-x anticoagulante
DE3886367D1 (de) Verwendung von Antigestagenen zur Herstellung von Arzneimitteln.
ES8702925A1 (es) Un procedimiento para preparar un polipeptido que tiene ac- tividad de factor de crecimiento